GSK has been found guilty of bringing discredit on the pharma industry after a complainan | GSK has been found guilty of ...

Walmsley says GSK is “incredibly intentional” in how the company recruits and trains talent. The company’s management has worked on ways to reduce their rate of misses when ...

The FDA will remove industry representatives from advisory committees and replace them with patients and caregivers ...

Some justices may be skeptical of a bid by GSK, Pfizer and others to overturn ruling allowing lawsuits to proceed over claims ...

Trump administration probing extent to which pharmaceutical imports may threaten national security, a likely prelude to ...

The pharma giant is wagering potentially billions of dollars on technology from ABL Bio that’s designed to get drugs across the blood-brain barrier.

GSK is paying to access ABL Bio’s Grabody-B platform, which potentially enables therapies to cross the blood-brain barrier.

As first quarter earnings begin, executives are confronting market turmoil, regulatory instability and the threat of U.S.

GSK has continued to flesh out its neuroscience strategy with a 2 billion pound sterling ($2.5 billion) deal to use a South ...

North Carolina is listed as a location for the manufacture of AstraZeneca and Sanofi's respiratory syncytial virus (RSV) prevention antibody, nirsevimab, as well as for GSK's two-drug HIV regimen ...

Pharmaceuticals are the next Trump tariff battleground - what will they mean for the NHS? - TRUMP TARIFFS: UK-based drug ...

It also makes it more expensive to bring drugs to market and could harm pharma companies' profits if they absorb some of the increased costs. As for investors, GSK and AstraZeneca are trying to ...